NOVO NORDISK A/S

NYSE: NVO (Novo Nordisk A/S)

Last update: 01 Aug, 11:46PM

48.19

1.12 (2.38%)

  • 1D 2.38%
  • 5D 6.19%
  • 1M -27.84%
  • 6M -46.80%
  • YTD -44.94%
  • 1Y -64.79%
  • 5Y 46.12%
Previous Close 47.07
Open 48.27
Volume 34,693,939
Avg. Volume (3M) 12,924,509
Market Cap 213,983,363,072
Price / Earnings (TTM) 13.42
Price / Earnings (Forward) 13.19
Price / Sales 4.67
Price / Book 8.65
52 Weeks Range
46.90 (-2%) — 139.74 (189%)
Earnings Date 6 Aug 2025
TTM Dividend Yield 2.28%
Profit Margin 34.51%
Operating Margin (TTM) 49.68%
Diluted EPS (TTM) 3.67
Quarterly Revenue Growth (YOY) 19.50%
Quarterly Earnings Growth (YOY) 14.30%
Total Debt/Equity (MRQ) 85.70%
Current Ratio (MRQ) 0.740
Operating Cash Flow (TTM) 131.24 B
Levered Free Cash Flow (TTM) 77.73 B
Return on Assets (TTM) 23.29%
Return on Equity (TTM) 88.12%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Mixed Mixed
Drug Manufacturers - General (Global) Mixed Mixed
Stock Novo Nordisk A/S Bullish Bearish

AIStockmoo Score

0.6
Analyst Consensus 2.0
Insider Activity NA
Price Volatility 4.5
Technical Moving Averages 0.0
Technical Oscillators -4.0
Average 0.63

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
NVO 214 B 2.28% 13.42 8.65
LLY 632 B 0.58% 46.08 34.40
NVS 244 B 3.23% 19.11 5.87
MRK 211 B 2.82% 13.04 4.12
JNJ 431 B 2.08% 19.16 5.42
ABBV 364 B 2.34% 97.72 50.46

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Growth
% Held by Insiders 0.01%
% Held by Institutions 9.85%

Ownership

Name Date Shares Held
Everett Harris & Co /Ca/ 31 Mar 2025 6,408,022
52 Weeks Range
46.90 (-2%) — 139.74 (189%)
Median 70.00 (45.26%)
Total 1 Buy
Firm Date Target Price Call Price @ Call
TD Cowen 19 Aug 2025 70.00 (45.26%) Buy 50.90

No data within this time range.

  • 3M
Date Type Details
21 Aug 2025 CNBC FDA approves first-ever glucose monitoring system for weight loss from Signos 
20 Aug 2025 Announcement Novo Nordisk to present Wegovy® and Ozempic® data showing life-saving cardiovascular benefits for people living with obesity and type 2 diabetes at the European Society of Cardiology Congress 2025
19 Aug 2025 Announcement BioMed X and Novo Nordisk Launch New Collaboration in Oral Peptide Drug Delivery
19 Aug 2025 CNBC Viking Therapeutics shares fall 40% on disappointing obesity pill trial data
18 Aug 2025 CNBC Novo Nordisk offers diabetes drug Ozempic for less than half the price for cash-paying U.S. patients
15 Aug 2025 Announcement Wegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis
15 Aug 2025 Announcement Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH
07 Aug 2025 CNBC Eli Lilly shares drop after obesity pill shows modest late-stage trial results
06 Aug 2025 Announcement Novo Nordisk's sales increased by 16% in Danish kroner and by 18% at constant exchange rates to DKK 154.9 billion in the first six months of 2025
31 Jul 2025 CNBC Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
31 Jul 2025 CNBC Eli Lilly’s Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity
29 Jul 2025 Announcement Novo Nordisk lowers sales and operating profit outlook for 2025
29 Jul 2025 Announcement Maziar Mike Doustdar appointed as president and chief executive officer of Novo Nordisk
25 Jul 2025 Announcement European regulatory authority adopts positive opinion for Novo Nordisk’s Alhemo® (concizumab), recommending label expansion to treat haemophilia A and B without inhibitors
21 Jul 2025 CNBC Weight loss drugs could be a gamechanger for women with a common hormonal disorder
09 Jul 2025 CNBC Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
28 Jun 2025 Announcement HIMS INVESTOR NOTICE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
26 Jun 2025 Announcement Novo Nordisk continues efforts to support patient access to authentic, FDA approved Wegovy® and prioritize patient safety
23 Jun 2025 CNBC Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 34%
23 Jun 2025 Announcement Novo Nordisk terminates collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing
23 Jun 2025 Announcement Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities
22 Jun 2025 Announcement Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress
22 Jun 2025 Announcement Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine
20 Jun 2025 Announcement Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025
20 Jun 2025 Announcement Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
12 Jun 2025 Announcement Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development
11 Jun 2025 Announcement Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule
10 Jun 2025 Announcement ADA 2025: Novo Nordisk highlights strong portfolio data with new semaglutide and CagriSema results, redefining possibilities in obesity and diabetes care
22 May 2025 Announcement New Novo Nordisk initiatives support patient access to authentic, FDA-approved Wegovy® as federal ban on mass compounding of "semaglutide" takes effect
Show more
TTM Dividend Yield 2.28%
5Y Average Dividend Yield 2.48%
Payout Ratio 47.09%
Expected Next Dividend Payment Apr 2026
Ex Date Announcement Date Payment Date Details
31 Mar 2025 05 Feb 2025 08 Apr 2025 1.099206 Cash
16 Aug 2024 06 Aug 2024 26 Aug 2024 0.5126402 Cash
22 Mar 2024 31 Jan 2024 02 Apr 2024 0.92985 Cash
18 Aug 2023 10 Aug 2023 29 Aug 2023 0.8835613 Cash
24 Mar 2023 02 Feb 2023 04 Apr 2023 1.1887415 Cash
12 Aug 2022 04 Aug 2022 23 Aug 2022 0.5835507 Cash
25 Mar 2022 02 Mar 2022 05 Apr 2022 1.022423 Cash
16 Aug 2021 - 25 Aug 2021 0.5502889 Cash
26 Mar 2021 - 07 Apr 2021 0.922122 Cash
14 Aug 2020 06 Aug 2020 25 Aug 2020 0.5177774 Cash
27 Mar 2020 06 Feb 2020 07 Apr 2020 0.7826048 Cash
16 Aug 2019 10 Aug 2019 27 Aug 2019 0.449438 Cash
22 Mar 2019 05 Feb 2019 02 Apr 2019 0.777006 Cash
17 Aug 2018 09 Aug 2018 28 Aug 2018 0.462327 Cash
23 Mar 2018 24 Mar 2018 03 Apr 2018 0.805982 Cash
17 Aug 2017 - 29 Aug 2017 0.33589 Cash
23 Mar 2017 - 04 Apr 2017 0.479369 Cash
11 Aug 2016 - 23 Aug 2016 0.331026 Cash
18 Mar 2016 - 30 Mar 2016 0.69943 Cash
19 Mar 2015 - 31 Mar 2015 0.532885 Cash
21 Mar 2014 - 02 Apr 2014 0.606122 Cash
21 Mar 2013 - 02 Apr 2013 2.264307 Cash
22 Mar 2012 - 03 Apr 2012 1.831902 Cash
24 Mar 2011 - 05 Apr 2011 1.357901 Cash
25 Mar 2010 - 07 Apr 2010 0.978615 Cash
19 Mar 2009 - 31 Mar 2009 0.781532 Cash
13 Mar 2008 - 25 Mar 2008 0.678462 Cash
08 Mar 2007 - 20 Mar 2007 0.891779 Cash
09 Mar 2006 - 21 Mar 2006 0.691753 Cash
10 Mar 2005 - 22 Mar 2005 0.61725 Cash
17 Mar 2004 - 29 Mar 2004 0.52096 Cash
26 Mar 2003 - 07 Apr 2003 0.37647 Cash
13 Mar 2002 - 25 Mar 2002 0.2848 Cash
21 Mar 2001 - 02 Apr 2001 0.5681 Cash
24 Mar 2000 - 06 Apr 2000 0.4672 Cash
25 Mar 1999 - 06 Apr 1999 0.4182 Cash
27 Mar 1998 - 08 Apr 1998 0.3051 Cash
25 Apr 1997 - 07 May 1997 0.239 Cash
01 May 1996 - 14 May 1996 0.1806 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 1.10 1 2.28
2024 1.44 2 1.68
2023 2.07 2 2.00
2022 1.61 2 2.37
2021 1.47 2 2.63
2020 1.30 2 3.72
2019 1.23 2 4.24
2018 1.27 2 5.51
2017 0.815 2 3.04
2016 1.03 2 5.75
2015 0.533 1 1.84
2014 0.606 1 2.86
2013 2.26 1 12.26
2012 1.83 1 11.22
2011 1.36 1 11.78
2010 0.979 1 8.69
2009 0.782 1 12.24
2008 0.678 1 13.20
2007 0.892 1 13.75
2006 0.692 1 16.54
2005 0.617 1 21.94
2004 0.521 1 19.20
2003 0.376 1 18.38
2002 0.285 1 19.71
2001 0.568 1 28.33
2000 0.467 1 26.40
1999 0.418 1 32.36
1998 0.305 1 22.94
1997 0.239 1 16.57
1996 0.181 1 19.32
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria